reports
- Hilde Van Boxstael
- Livio Luyten
- Wim Lewi
- Livio Luyten
TINC 1H25 Results: Updating our NAV Forecast model
In light of TINC's strong 1H25, we updated our model and projections. In 1H25, the portfolio fair value rose to €649.3m, up 26.8% from FY24-end. This is in line with our expectation of €671.1m for FY25. Long-term portfolio growth assumptions remained roughly the same, taking into account the €110.8m in commitments and an estimated €100.0m in new investments. We anticipate that the current credit facility gives TINC a runway of 3 years. For FY30, we revise our expected NAV from ~€830m or 17.2ps t...
- Livio Luyten
- Lynn Hautekeete
- Wim Lewi
- Wedbush Research
- Laura Chico
- Jacob Mekhael
Pharvaris 2Q25 update shows all is on track, on-demand phase 3 readout...
Pharvaris reported 2Q25 results showing no major surprises and confirming previously communicated timelines, with the next key milestone being topline results from the phase 3 trial of deucrictibant (B2R antagonist, oral tablet) in on-demand HAE in 4Q25 – we are confident in a positive outcome. The company reported a cash position of $ 200m (YE24: $281m), which was supplemented by $ 201m in a public offering in July 2025, providing Pharvaris with a cash runway into 1H27. We continue to see Pharv...
- Wedbush Research
FATE FATE THERAPEUTICS INC
BIIB BIOGEN INC.
SE SEA ADS
STOK STOKE THERAPEUTICS
PASG PASSAGE BIO
ORIC ORIC PHARMACEUTICALS
GBIO GENERATION BIO
VOR VOR BIOPHARMA
PHVS PHARVARIS NV
ATXS ASTRIA THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
SLDB SOLID BIOSCIENCES INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
RNAC CARTESIAN THERAPEUTICS INC
MAZE MAZE THERAPEUTICS INC
- Jacob Mekhael
- Wim Hoste
- Wim Lewi
- Laura Chico
Pharvaris Reports Second Quarter 2025 Financial Results and Provides B...
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks, on track; study is expected to initiate by YE2025Strong financial position with cash and cash equ...
- Livio Luyten
Holdings Report - July 2025 KBCS Holdings Universe Returns -0.5% Durin...
1M Performance - Absolute Total Return: During Jul'25 (1M period), the KBCS Holdings Universe posted a total return of -0.5% which was mainly driven by the performance of the multi-asset holdings (-0.9%), while the single-asset holdings posted a return of +0.4%. The 3 top performers during the period were Financière de Tubize (+11.7%), KBC Ancora (+9.4%) and Quest For Growth (+5.5%) while the 3 worst performers were Brederode (-6.4%), Heineken Holding (-5.0%) and D'Ieteren Group (-4.7%). YTD Pe...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
EXO EXOR N.V.
- Jerôme Bodin
- Steven Boumans
APAML APERAM SA
LI KLEPIERRE SA
COV COVIVIO SA
OUT1V OUTOKUMPU OYJ
GFC GECINA SA
NXI NEXITY SA CLASS A
FLY SOCIETE FONCIERE LYONNAISE SA
GYC GRAND CITY PROPERTIES SA
F3C SFC ENERGY AG
MERY MERCIALYS SA
DEC JCDECAUX SA
INEA FONCIERE INEA
VIV VIVENDI SE
WHA WERELDHAVE N.V.
SRP SRP GROUPE SA
PSM PROSIEBENSAT.1 MEDIA SE
BLND BRITISH LAND COMPANY PLC
MRN MERSEN SA
KOF KAUFMAN & BROAD SA
ALTA ALTAREA SCA
VNA VONOVIA SE
ACX ACERINOX SA
XIOR XIOR STUDENT HOUSING N.V.
ICAD ICADE SA
BYG BIG YELLOW GROUP PLC
COFB COFINIMMO SA
SOC SUBSEA 7 S.A.
CAI CA IMMOBILIEN ANLAGEN AG
TEG TAG IMMOBILIEN AG
COK CANCOM SE
VASTB VASTNED RETAIL BELGIUM NV
DLG DE'LONGHI S.P.A.
PSPN PSP SWISS PROPERTY AG
UBS UBM DEVELOPMENT AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
CPINV CARE PROPERTY INVEST SA
BRNL BRUNEL INTERNATIONAL N.V.
GCO GRUPO CATALANA OCCIDENTE S.A.
SAFE SAFESTORE HOLDINGS PLC
ARG ARGAN SA
VGP VGP NV
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
WLN WORLDLINE SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
DKG DEUTSCHE KONSUM REIT-AG
TRE TECNICAS REUNIDAS SA
XFAB X-FAB SILICON FOUNDRIES SE
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
UMI UMICORE
NSI NSI N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
AEDAS AEDAS HOMES SA
NEXI NEXI S.P.A.
CLA CLARANOVA SE
WDP WAREHOUSES DE PAUW SCA
TE TECHNIP ENERGIES NV
AERO MONTANA AEROSPACE AG
ECMPA EUROCOMMERCIAL PROPERTIES NV
FUR FUGRO NV
CTPNV CTP NV
ONE ONE UNITED PROPERTIES SA
FLE PEGASUS ENTREPRENEURIAL ACQUISITION CO EURO BV
SHUR SHURGARD SELF STORAGE LIMITED
PLNW PLANISWARE
VIRI VIRIDIEN
AMS AMS-OSRAM AG
- Jerôme Bodin
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
F3C SFC ENERGY AG
DEC JCDECAUX SA
VIV VIVENDI SE
SRP SRP GROUPE SA
PSM PROSIEBENSAT.1 MEDIA SE
MRN MERSEN SA
ACX ACERINOX SA
SOC SUBSEA 7 S.A.
COK CANCOM SE
DLG DE'LONGHI S.P.A.
BRNL BRUNEL INTERNATIONAL N.V.
GCO GRUPO CATALANA OCCIDENTE S.A.
WLN WORLDLINE SA
TRE TECNICAS REUNIDAS SA
XFAB X-FAB SILICON FOUNDRIES SE
UMI UMICORE
NEXI NEXI S.P.A.
CLA CLARANOVA SE
TE TECHNIP ENERGIES NV
AERO MONTANA AEROSPACE AG
FUR FUGRO NV
FLE PEGASUS ENTREPRENEURIAL ACQUISITION CO EURO BV
PLNW PLANISWARE
VIRI VIRIDIEN
AMS AMS-OSRAM AG
- Martijn Den Drijver
- ING Helpdesk
Benelux Morning Notes
Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new S...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Wim Hoste
Umicore FIRST LOOK: 1H adj EBITDA +10%, recently upped guidance reiter...
1H25 adj. EBITDA increased by 10% to 433m and Umicore reiterated the (recently upgraded) FY25 adj EBITDA guidance of 790-840m (+7% y/y at midpoint), reflecting oa the progress with efficiency improvement measures and advantageous metal prices. Umicore is a combination of different tales, with the foundation businesses (Catalysis, Recycling, Specialty Materials) mainly run for their cash generation potential whilst Battery Materials remains a potential growth driver, although Umicore does not int...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering ...
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the closing of its previ...
- Jacob Mekhael
Pharvaris Raises $ 175m in gross proceeds via public offering
Pharvaris announced the pricing of an upsized public offering of 8,250,000 ordinary shares at a price of $ 20 per share (13.49% discount to previous close), and to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $ 19.99 per pre-funded warrant for gross proceeds of approx. $ 175m. We expect the net proceeds to extend Pharvaris' cash runway to mid-2027 (KBCSe) from 2H26, and will be used for R&D as well as commercialisation preparations in the US. We update our ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.